Follicular lymphoma grade IIIa, unspecified site
ICD-10 C82.30 is a billable code used to indicate a diagnosis of follicular lymphoma grade iiia, unspecified site.
Follicular lymphoma is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. Grade IIIa indicates a higher grade of malignancy, where the lymphoma exhibits a more aggressive behavior compared to lower grades. This grade is defined by the presence of a higher percentage of large cells (greater than 25% of the tumor) in the histological examination. The unspecified site designation indicates that the lymphoma is not localized to a specific anatomical location, which can complicate treatment and management strategies. Patients may present with B-symptoms, which include fever, night sweats, and weight loss, indicating systemic involvement. Treatment protocols often involve a combination of chemotherapy, immunotherapy, and possibly radiation, depending on the stage of the disease and the patient's overall health. The prognosis for patients with grade IIIa follicular lymphoma can vary significantly based on individual factors, including age, performance status, and response to initial therapy.
Detailed pathology reports, treatment plans, and follow-up notes are essential.
Diagnosis confirmation through biopsy, treatment initiation, and monitoring of treatment response.
Ensure accurate grading and staging documentation to support treatment decisions.
Comprehensive histological reports detailing cell types and grading.
Histological examination of biopsy samples to confirm diagnosis.
Clear communication of findings to the treating physician is crucial for accurate coding.
Used during treatment of follicular lymphoma grade IIIa.
Document the specific chemotherapy agents used and the patient's response.
Oncology specialists must ensure accurate coding of chemotherapy regimens.
Common treatments include chemotherapy, immunotherapy, and sometimes radiation therapy, depending on the patient's overall health and disease stage.
